Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6

Virology

Volumn 458-459, Issue 1, 2014, Pages 190-208

  Mathiesen, Christian K ^a,b   Jensen, Tanja B ^a,b   Prentoe, Jannick ^a,b   Krarup, Henrik ^c   Nicosia, Alfredo ^d,e,f   Law, Mansun ^g   Bukh, Jens ^a,b   Gottwein, Judith M ^a,b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Okairos ^*  (Italy)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Adenovirus expression medium; Biophysical characterization; Cell culture system; Genotypes; Hepatitis C virus; High titer; Neutralization; Receptor blocking; Serum free; Vaccine development

Indexed keywords

APOLIPOPROTEIN E; CD81 ANTIGEN; CLATHRIN; EPITOPE; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; SCAVENGER RECEPTOR BI;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOCYTOSIS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HEPATOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS RELEASE;

ADENOVIRUS EXPRESSION MEDIUM; BIOPHYSICAL CHARACTERIZATION; CELL CULTURE SYSTEM; GENOTYPES; HEPATITIS C VIRUS; HIGH-TITER; NEUTRALIZATION; RECEPTOR BLOCKING; SERUM-FREE; VACCINE DEVELOPMENT;

CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; VIRUS CULTIVATION;

EID: 84901218440     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.03.021     Document Type: Article

References (77)

1. Abdo A.A., Lee S.S. Management of hepatitis C virus genotype 4. J. Gastroenterol. Hepatol. 2004, 19:1233-1239.
2. Abe K., Ikeda M., Ariumi Y., Dansako H., Kato N. Serum-free cell culture system supplemented with lipid-rich albumin for hepatitis C virus (strain O of genotype 1b) replication. Virus Res. 2007, 125:162-168.
3. Akazawa D., Morikawa K., Omi N., Takahashi H., Nakamura N., Mochizuki H., et al. Production and characterization of HCV particles from serum-free culture. Vaccine 2011, 29:4821-4828.
4. Akazawa D., Moriyama M., Yokokawa H., Omi N., Watanabe N., Date T., et al. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Gastroenterology 2013, 145:447-455.
5. Albecka A., Belouzard S., Beeck D., Op A., Descamps V., Goueslain L., et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 2012, 55:998-1007.
6. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 2000, 20:17-36.
7. Amoroso P., Rapicetta M., Tosti M.E., Mele A., Spada E., Buonocore S., et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. J. Hepatol. 1998, 28:939-944.
8. Bankwitz D., Steinmann E., Bitzegeio J., Ciesek S., Friesland M., Herrmann E., et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 2010, 84:5751-5763.
9. Blanchard E., Belouzard S., Goueslain L., Wakita T., Dubuisson J., Wychowski C., et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2006, 80:6964-6972.
10. Bukh J., Meuleman P., Tellier R., Engle R.E., Feinstone S.M., Eder G., et al. Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J. Infect. Dis. 2010, 201:1381-1389.
11. Catanese M.T., Graziani R., von Hahn T., Moreau M., Huby T., Paonessa G., et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J. Virol. 2007, 81:8063-8071.
12. Catanese M.T., Uryu K., Kopp M., Edwards T.J., Andrus L., Rice W.J., et al. Ultrastructural analysis of hepatitis C virus particles. Proc. Natl. Acad. Sci. USA 2013, 110:9505-9510.
13. Chang K.-S., Jiang J., Cai Z., Luo G. Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 2007, 81:13783-13793.
14. Costa D.D., Turek M., Felmlee D.J., Girardi E., Pfeffer S., Long G., et al. Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J. Virol. 2012, 86:11919-11925.
15. Cross T.J.S., Rashid M.M., Berry P.A., Harrison P.M. The importance of steatosis in chronic hepatitis C infection and its management: a review. Hepatol. Res. 2010, 40:237-247.
16. Dhillon S., Witteveldt J., Gatherer D., Owsianka A.M., Zeisel M.B., Zahid M.N., et al. Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J. Virol. 2010, 84:5494-5507.
17. Fauvelle C., Lepiller Q., Felmlee D.J., Fofana I., Habersetzer F., Stoll-Keller F., et al. Hepatitis C virus vaccines-progress and perspectives. Microb. Pathog. 2013, 58:66-72.
18. Felmlee D., Hafirassou M., Lefevre M., Baumert T., Schuster C. Hepatitis C virus, cholesterol and lipoproteins-impact for the viral life cycle and pathogenesis of liver disease. Viruses 2013, 5:1292-1324.
19. Frentzen A., Anggakusuma, Gürlevik E., Hueging K., Knocke S., Ginkel C., et al. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Hepatology 2014, 59:78-88.
20. Gastaminza P., Kapadia S.B., Chisari F.V. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J. Virol. 2006, 80:11074-11081.
21. Gastaminza P., Dryden K.A., Boyd B., Wood M.R., Law M., Yeager M., et al. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J. Virol. 2010, 84:10999-11009.
22. Giang E., Dorner M., Prentoe J.C., Dreux M., Evans M.J., Bukh J., et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. USA 2012, 109:6205-6210.
23. Gottwein J.M., Bukh J. Cutting the Gordian Knot-development and biological relevance of hepatitis C virus cell culture systems. Adv. Virus Res. 2008, 71:51-133.
24. Gottwein J.M., Bukh J. Viral hepatitis: cell-culture-derived HCV-a promising vaccine antigen. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:508-509.
25. Gottwein J.M., Scheel T.K., Hoegh A.M., Lademann J.B., Eugen-Olsen J., Lisby G., et al. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 2007, 133:1614-1626.
26. Gottwein J.M., Scheel T.K., Jensen T.B., Lademann J.B., Prentoe J.C., Knudsen M.L., et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009, 49:364-377.
27. Gottwein J.M., Scheel T.K.H., Callendret B., Li Y.-P., Eccleston H.B., Engle R.E., et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J. Virol. 2010, 84:5277-5293.
28. Gottwein J.M., Scheel T.K.H., Jensen T.B., Ghanem L., Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011, 141:1067-1079.
29. Grove J., Nielsen S., Zhong J., Bassendine M.F., Drummer H.E., Balfe P., et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 2008, 82:12020-12029.
30. Horwitz J.A., Dorner M., Friling T., Donovan B.M., Vogt A., Loureiro J., et al. Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein. Virology 2013, 439:23-33.
31. Houghton M., Law J.L., Tyrrell D.L. An inactivated hepatitis C virus vaccine on the horizon?. Gastroenterology 2013, 145:285-288.
32. Jensen T.B., Gottwein J.M., Scheel T.K.H., Hoegh A.M., Eugen-Olsen J., Bukh J. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 2008, 198:1756-1765.
33. Jiang J., Luo G. Cell culture-adaptive mutations promote viral protein-protein interactions and morphogenesis of infectious hepatitis C virus. J. Virol. 2012, 86:8987-8997.
34. Kambara H., Fukuhara T., Shiokawa M., Ono C., Ohara Y., Kamitani W., et al. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J. Virol. 2012, 86:1382-1393.
35. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 2008, 14:25-27.
36. Lindenbach B.D., Evans M.J., Syder A.J., Wölk B., Tellinghuisen T.L., Liu C.C., et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
37. Lindenbach B.D., Meuleman P., Ploss A., Vanwolleghem T., Syder A.J., McKeating J.A., et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. USA 2006, 103:3805-3809.
38. Liu S., Xiao L., Nelson C., Hagedorn C., Cell A. Culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses. PLoS ONE 2012, 7:e44965.
39. Lohmann V., Bartenschlager R. On the history of hepatitis C virus cell culture systems. J. Med. Chem. 2014, 57:1627-1642.
40. McKeating J.A., Zhang L.Q., Logvinoff C., Flint M., Zhang J., Yu J., et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J. Virol. 2004, 78:8496-8505.
41. Meertens L., Bertaux C., Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J. Virol. 2006, 80:11571-11578.
42. Merz A., Long G., Hiet M.-S., Brugger B., Chlanda P., Andre P., et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J. Biol. Chem. 2010, 286:3018-3032.
43. Meunier J.-C., Engle R.E., Faulk K., Zhao M., Bartosch B., Alter H., et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl. Acad. Sci. USA 2005, 102:4560-4565.
44. Nakabayashi H., Taketa K., Miyano K., Yamane T., Sato J. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res. 1982, 42:3858-3863.
45. Narbus C.M., Israelow B., Sourisseau M., Michta M.L., Hopcraft S.E., Zeiner G.M., et al. HepG2 cells expressing microrNA miR-122 support the entire hepatitis C virus life cycle. J. Virol. 2011, 85:12087-12092.
46. Nielsen S.U., Bassendine M.F., Burt A.D., Martin C., Pumeechockchai W., Toms G.L. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 2006, 80:2418-2428.
47. Owen D.M., Huang H., Ye J., Gale M. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009, 394:99-108.
48. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 2006, 103:7408-7413.
49. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., et al. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
50. Ploss A., Evans M.J. Hepatitis C virus host cell entry. Curr. Opin. Virol. 2012, 2:14-19.
51. Plotkin S.A. Correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008, 47:401-409.
52. Plotkin S.A., Plotkin S.L. The development of vaccines: how the past led to the future. Nat. Rev. Microbiol. 2011, 9:889-893.
53. Pokrovskii M.V., Bush C.O., Beran R.K.F., Robinson M.F., Cheng G., Tirunagari N., et al. Novel mutations in a tissue culture-adapted hepatitis C virus strain improve infectious-virus stability and markedly enhance infection kinetics. J. Virol. 2011, 85:3978-3985.
54. Popescu C.-I., Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol. Cell 2010, 102:63-74.
55. Prentoe J., Jensen T.B., Meuleman P., Serre S.B.N., Scheel T.K.H., Leroux-Roels G., et al. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J. Virol. 2011, 85:2224-2234.
56. Prentoe J., Serre S.B.N., Ramirez S., Nicosia A., Gottwein J.M., Bukh J. Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus. J. Virol. 2014, 88:1725-1739.
57. Russell R.S., Meunier J.-C., Takikawa S., Faulk K., Engle R.E., Bukh J., et al. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc. Natl. Acad. Sci. USA 2008, 105:4370-4375.
58. Sarrazin C., Hézode C., Zeuzem S., Pawlotsky J.-M. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 2012, 56:S88-S100.
59. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21:5017-5025.
60. Scheel T.K., Gottwein J.M., Jensen T.B., Prentoe J.C., Hoegh A.M., Alter H.J., et al. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. USA 2008, 105:997-1002.
61. Scheel T.K.H., Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 2013, 19:837-849.
62. Scheel T.K.H., Gottwein J.M., Mikkelsen L.S., Jensen T.B., Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology 2011, 140:1032-1042.
63. Scheel T.K.H., Prentoe J., Carlsen T.H.R., Mikkelsen L.S., Gottwein J.M., Bukh J. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems. PLoS Pathog. 2012, 8:e1002696.
64. Serre S.B.N., Krarup H.B., Bukh J., Gottwein J.M. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. J. Virol. 2013, 87:12776-12793.
65. Simmonds P., Bukh J., Combet C., Deléage G., Enomoto N., Feinstone S., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
66. Sourisseau M., Goldman O., He W., Gori J.L., Kiem H., Gouon-Evans V., et al. Hepatic cells derived from induced pluripotent stem cells of pigtail macaques support hepatitis C virus infection. Gastroenterology 2013, 145:966-969.
67. Steinmann E., Pietschmann T. Cell culture systems for hepatitis C virus. Curr. Top. Microbiol. Immunol. 2013, 369:17-48.
68. Thi V.L.D., Granier C., Zeisel M.B., Guerin M., Mancip J., Granio O., et al. Characterization of hepatitis C virus particle sub-populations reveals multiple usage of the scavenger receptor BI for entry steps. J. Biol. Chem. 2012, 287:31242-31257.
69. Vogt A., Scull M.A., Friling T., Horwitz J.A., Donovan B.M., Dorner M., et al. Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology 2013, 444:1-11.
70. WHO Requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological susbstances no. 50). Biologicals 1998, 26:175-193.
71. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
72. Weisgraber K.H., Innerarity T.L., Harder K.J., Mahley R.W., Milne R.W., Marcel Y.L., et al. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J. Biol. Chem. 1983, 258:12348-12354.
73. Wünschmann S., Müller H.M., Stipp C.S., Hemler M.E., Stapleton J.T. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. J. Infect. Dis. 2006, 194:1058-1067.
74. Yamamoto M., Aizaki H., Fukasawa M., Teraoka T., Miyamura T., Wakita T., et al. Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus. J. Gen. Virol. 2011, 92:2082-2087.
75. Yi M., Ma Y., Yates J., Lemon S.M. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J. Virol. 2007, 81:629-638.
76. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., et al. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 2005, 102:9294-9299.
77. Zhong J., Gastaminza P., Chung J., Stamataki Z., Isogawa M., Cheng G., et al. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J. Virol. 2006, 80:11082-11093.